Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The overall purpose of the study is to investigate the efficacy and safety of ALECSAT in
patients with relapse of GlioBlastoma Multiforme (GBM) after first line treatments (followed
by reoperation if possible). The efficacy and safety of ALECSAT treatment is, compared to
standard Bevacizumab/Irinotecan second line treatments for these patients.